[{"id":"38f71642-9963-4119-8080-8fd4152ee9d4","acronym":"NCI9922","url":"https://clinicaltrials.gov/study/NCT02581930","created_at":"2021-01-18T12:31:19.061Z","updated_at":"2024-07-02T16:35:02.824Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma","source_id_and_acronym":"NCT02581930 - NCI9922","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • LAG3 • CTLA4 • ERBB4 • CD40","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • LAG3 • CTLA4 • ERBB4 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/17/2016","start_date":" 08/17/2016","primary_txt":" Primary completion: 02/10/2018","primary_completion_date":" 02/10/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-17"},{"id":"04df3049-aecf-4362-a49a-2285288f64a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05075993","created_at":"2021-10-13T16:58:12.200Z","updated_at":"2024-07-02T16:35:11.360Z","phase":"Phase 1","brief_title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","source_id_and_acronym":"NCT05075993","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • cyclophosphamide intravenous • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)"],"overall_status":"Recruiting","enrollment":" Enrollment 352","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 02/02/2027","primary_completion_date":" 02/02/2027","study_txt":" Completion: 02/02/2027","study_completion_date":" 02/02/2027","last_update_posted":"2024-04-04"},{"id":"313cce70-347b-44fa-8592-5bfdfa424f9b","acronym":"HSBRT2402","url":"https://clinicaltrials.gov/study/NCT06313190","created_at":"2024-03-15T21:36:53.401Z","updated_at":"2024-07-02T16:35:14.523Z","phase":"Phase 2","brief_title":"Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)","source_id_and_acronym":"NCT06313190 - HSBRT2402","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • IL2RA • CD40","pipe":"","alterations":" ","tags":["IL6 • IL2RA • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/05/2024","start_date":" 04/05/2024","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2024-03-15"},{"id":"0f4f4db7-864a-4af4-9ed3-894c0ed55bd1","acronym":"HSBRT2401","url":"https://clinicaltrials.gov/study/NCT06261125","created_at":"2024-02-15T17:26:46.872Z","updated_at":"2024-07-02T16:35:15.217Z","phase":"Phase 2","brief_title":"Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)","source_id_and_acronym":"NCT06261125 - HSBRT2401","lead_sponsor":"Mian XI","biomarkers":" IL6 • IL2RA • CD40","pipe":"","alterations":" ","tags":["IL6 • IL2RA • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/10/2024","start_date":" 03/10/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-03-12"},{"id":"adb47411-e4ca-44c0-af22-a98798c3a97a","acronym":"EC-CRT-007","url":"https://clinicaltrials.gov/study/NCT06187597","created_at":"2024-01-02T14:16:57.201Z","updated_at":"2024-07-02T16:35:15.221Z","phase":"Phase 2","brief_title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","source_id_and_acronym":"NCT06187597 - EC-CRT-007","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40","pipe":"","alterations":" ","tags":["IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-12"},{"id":"9ce2998a-b97d-42c7-814f-e91e27b1b1ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03719430","created_at":"2024-02-02T19:19:38.476Z","updated_at":"2024-07-02T16:35:15.675Z","phase":"Phase 2","brief_title":"APX005M and Doxorubicin in Advanced Sarcoma","source_id_and_acronym":"NCT03719430","lead_sponsor":"Alexander Z. Wei, MD","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-08"},{"id":"95501520-56c2-4384-b4db-b35ffc085951","acronym":"REACtiVe-2","url":"https://clinicaltrials.gov/study/NCT05650918","created_at":"2022-12-14T14:58:22.504Z","updated_at":"2024-07-02T16:35:33.672Z","phase":"Phase 1","brief_title":"MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)","source_id_and_acronym":"NCT05650918 - REACtiVe-2","lead_sponsor":"Joachim Aerts, MD PhD","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MesoPher (autologous dendritic cell vaccine) • mitazalimab (ADC-1013)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 05/23/2023","primary_completion_date":" 05/23/2023","study_txt":" Completion: 05/23/2023","study_completion_date":" 05/23/2023","last_update_posted":"2023-10-12"},{"id":"b6df07b6-a88e-4791-862f-2c9826b94a75","acronym":"LIFT","url":"https://clinicaltrials.gov/study/NCT01275209","created_at":"2021-02-26T05:52:10.861Z","updated_at":"2024-07-02T16:36:37.648Z","phase":"Phase 1","brief_title":"Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma","source_id_and_acronym":"NCT01275209 - LIFT","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • LymphoCide Y-90 (epratuzumab Y-90) • lucatumumab (CHIR 12.12)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2020-12-08"},{"id":"af305bb7-595f-4af9-bc17-4d80012623d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01103635","created_at":"2021-02-26T05:52:10.499Z","updated_at":"2024-07-02T16:36:46.439Z","phase":"Phase 1","brief_title":"Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01103635","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imjudo (tremelimumab-actl) • CP-870893"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/02/2016","study_completion_date":" 05/02/2016","last_update_posted":"2020-04-07"},{"id":"7a9b8663-cf30-46c6-9cce-322b403ff89a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03427398","created_at":"2021-01-18T16:54:26.230Z","updated_at":"2024-07-02T16:37:08.307Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma","source_id_and_acronym":"NCT03427398","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • LAG3 • CTLA4 • CD40","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • LAG3 • CTLA4 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/17/2016","start_date":" 08/17/2016","primary_txt":" Primary completion: 02/10/2018","primary_completion_date":" 02/10/2018","study_txt":"","study_completion_date":"","last_update_posted":"2018-08-03"},{"id":"63845dd5-f2cd-4888-8524-44b5ad7386d1","acronym":"GPAS","url":"https://clinicaltrials.gov/study/NCT02887417","created_at":"2021-01-18T14:10:16.874Z","updated_at":"2024-07-02T16:37:19.312Z","phase":"","brief_title":"Glioblastoma Platelet Activation Study","source_id_and_acronym":"NCT02887417 - GPAS","lead_sponsor":"University Medicine Greifswald","biomarkers":" CD40","pipe":" | ","alterations":" CD40 expression","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD40 expression"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-08-01"},{"id":"695a8f0a-8022-4d0c-9439-2ec7fd2bbea6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00607048","created_at":"2021-01-18T02:15:12.023Z","updated_at":"2024-07-02T16:37:24.096Z","phase":"Phase 1","brief_title":"Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors","source_id_and_acronym":"NCT00607048","lead_sponsor":"Hoffmann-La Roche","biomarkers":" IL6 • TNFA • ICAM1 • CD40 • CD86 • FCER2","pipe":"","alterations":" ","tags":["IL6 • TNFA • ICAM1 • CD40 • CD86 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • CP-870893"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 07/01/2009","study_completion_date":" 07/01/2009","last_update_posted":"2017-03-27"}]